Relay Therapeutics (RLAY) Accumulated Expenses (2019 - 2026)

Relay Therapeutics (RLAY) has reported Accumulated Expenses for 8 consecutive years, with $20.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses changed 0.37% year-over-year to $20.9 million; the TTM figure through Mar 2026 stood at $20.9 million (changed 0.37% YoY), while the FY2025 annual figure was $13.6 million, down 35.75% from the prior year.
• Accumulated Expenses climbed to $20.9 million in Q1 2026 per RLAY's latest filing, from $13.6 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $33.2 million in Q3 2024 and bottomed at $13.6 million in Q4 2025.
• Historically, Accumulated Expenses has averaged $23.5 million across 5 years, with a median of $22.7 million in 2022.
• Annual changes were most pronounced in 2023 — Accumulated Expenses jumped 84.3% — and 2025, when it sank 35.75%.
• Relay Therapeutics' Accumulated Expenses stood at $22.7 million in 2022, then plunged by 34.41% to $14.9 million in 2023, then jumped by 42.62% to $21.2 million in 2024, then tumbled by 35.75% to $13.6 million in 2025, then soared by 53.26% to $20.9 million in 2026.
• Business Quant data shows RLAY's Accumulated Expenses at $20.9 million in Q1 2026, $13.6 million in Q4 2025, and $25.1 million in Q3 2025.